Tags

Type your tag names separated by a space and hit enter

Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19.
Front Immunol. 2020; 11:1021.FI

Links

PMC Free PDF

Authors+Show Affiliations

Shah A
University of Ulm, Ulm, Germany.

MeSH

Antiviral AgentsCOVID-19Coronavirus InfectionsDrug Delivery SystemsHumansInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinPandemicsPneumonia, ViralSpike Glycoprotein, CoronavirusCOVID-19 Drug Treatment

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32574259

Citation

Shah, Adnan. "Novel Coronavirus-Induced NLRP3 Inflammasome Activation: a Potential Drug Target in the Treatment of COVID-19." Frontiers in Immunology, vol. 11, 2020, p. 1021.
Shah A. Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19. Front Immunol. 2020;11:1021.
Shah, A. (2020). Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19. Frontiers in Immunology, 11, 1021. https://doi.org/10.3389/fimmu.2020.01021
Shah A. Novel Coronavirus-Induced NLRP3 Inflammasome Activation: a Potential Drug Target in the Treatment of COVID-19. Front Immunol. 2020;11:1021. PubMed PMID: 32574259.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19. A1 - Shah,Adnan, Y1 - 2020/05/19/ PY - 2020/04/17/received PY - 2020/04/28/accepted PY - 2020/6/24/entrez PY - 2020/6/24/pubmed PY - 2020/7/11/medline KW - COVID-19 KW - NLRP3 inflammasome KW - SARS-CoV KW - cytokines KW - viroporins SP - 1021 EP - 1021 JF - Frontiers in immunology JO - Front Immunol VL - 11 SN - 1664-3224 UR - https://www.unboundmedicine.com/medline/citation/32574259/Novel_Coronavirus_Induced_NLRP3_Inflammasome_Activation:_A_Potential_Drug_Target_in_the_Treatment_of_COVID_19_ DB - PRIME DP - Unbound Medicine ER -